TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03213106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Low frequency (1Hz) transcranial magnetic stimulation aimed to the dentate nucleus contralateral to the most symptomatic side.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: The stimulation coil will be placed in the same spot as the TMS stimulation, but coil will not be attached to the TMS machine.
Study: NCT03020797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT03615586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: With Chaperone
Description: Female patients examined by male physicians in the presence of a female (nurse) chaperone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without Chaperone
Description: Female patients examined by male physicians without the presence of a female (nurse) chaperone.
Study: NCT02795871

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological and cognitive assessment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological and cognitive assessment

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological and cognitive assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological and cognitive assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological and cognitive assessment
Study: NCT03701932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMS and Lumosity®cognitive retraining
Description: The Lumosity® training includes exercises for speed, memory, attention, flexibility, and problem solving. Subjects will complete this battery while receiving TMS treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TMS and non cognitive computer games
Description: Subjects will play computer games while receiving TMS treatment.
Study: NCT02382887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tracheal intubation
Description: tracheal intubation with the Airtraq

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tracheal intubation
Description: tracheal intubation with the Airtraq

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airtraq

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiberscope
Study: NCT02461342

Intervention type: OTHER
Intervention: not intervention
Description: This is a cross-sectional study, no intervention was performed.
Study: NCT03146195

Intervention type: OTHER
Intervention: Dynamic Magnetic resonance imaging

Intervention type: OTHER
Intervention: Dynamic Magnetic resonance imaging
Study: NCT02571829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Oral, 600 mg x 1 a day, duration - according to response
Study: NCT04529525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
Study: NCT01244971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: 100mg, 3 times daily

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Moderate combined exercise, 50 minutes 3 times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + Acarbose
Description: See respective monotherapy description
Study: NCT03275038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai-Chi exercise
Description: Behavioral: Tai-Chi exercise
Study: NCT05086887

Intervention type: DIAGNOSTIC_TEST
Intervention: Malaria diagnostic tests (RDT and PCR) and serology for malaria and other parasitic diseases
Description: All individuals are tested. Individuals with demonstrated parasitic disease are referred to the Infectious diseases or Pediatric clinic for evaluation and treatment.
Study: NCT00895258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual placement and support plus cognitive training (IPS-CT)
Description: One IPS plus one CT session each week for 12 weeks
Study: NCT03275038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Behavioral: Aerobic exercise
Study: NCT01357759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-022
Description: IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MORAb-022
Description: IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
Study: NCT06231433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 Vaginal Laser
Description: CO2 Vaginal laser
Study: NCT00885300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cloxacillin
Description: cloxacillin 100mg/ml as catheter lock at the end of hemodialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin
Description: heparin 1000iu/ml as catheter lock at the end of hemodialysis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: heparin 1000iu/ml as catheter lock at the end of hemodialysis
Study: NCT02491424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct skeletal fixation of ITAP to lower limb amputees.
Description: Intraosseous Transcutaneous Amputation Prosthesis (ITAPTM) fitting. The core ITAP™ design comprises of three discrete sections, the proximal section, which is the intramedullary stem secured into the medullary canal, the soft tissue integration flange and the transcutaneous component that passes through the skin.
Study: NCT03497364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: 0.5 % bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection according to the height of subjects (1.7 ml for 173\~174cm, 1.65 ml for 170\~172cm, 1.6 ml for 168\~169cm, 1.55 ml for 165\~167cm, 1.5 ml for 163\~164cm, 1.45 ml for 160\~162cm, 1.4 ml for 158\~159cm, 1.35 ml for 155\~157cm, 1.3 ml for 153\~154cm, 1.25 ml for 150\~152cm, 1.2 ml for 148\~149cm)，1.15 ml for 145\~147cm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 0.5 % ropivacaine (1% ropivacaine (1.5 ml) + cerebrospinal fluid (1.5 ml)) was injection according to the height of subjects (2.300 ml for 173\~174cm, 2.225 ml for 170\~172cm, 2.15 0ml for 168\~169cm, 2.075 ml for 165\~167cm, 2.000 ml for 163\~164cm, 1.925 ml for 160\~162cm, 1.850 ml for 158\~159cm, 1.775 ml for 155\~157cm, 1.700 ml for 153\~154cm, 1.625 ml for 150\~152cm, 1.55 0ml for 148\~149cm, 1.475 ml for 145\~147cm)
Study: NCT01057485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation and AV node ablation
Description: AF ablation and AV node ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AV node ablation
Description: AV node ablation
Study: NCT03320330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pepinemab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02832024

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plaque excision system
Study: NCT00895258

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual placement and support plus enhanced support (IPS-ES)
Description: One IPS plus one ES session each week for 12 weeks
Study: NCT02583776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unblinded - CGM
Description: Data from device will be readable and alarms on
Study: NCT02832024

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon
Study: NCT02737150

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoreValve Evolut R

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoreValve Evolut R

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Edwards Sapien 3

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Edwards Sapien 3

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with conscious sedation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with conscious sedation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Study: NCT02319135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitadine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenograstim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgastrim
Study: NCT04097977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work) targeting young people with mental health difficulties.
Description: An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work).~Intervention The RENEW-S intervention consists of two key elements: collaborative networking and a youth group.~Network meetings The RENEW-S network meetings is fundamental for this approach. First meeting between the young person and the facilitator is about what the young person can expect, and information about the principles and ideas behind RENEW-S. The RENEW-S process consists of 4 general phases: 1) a mapping process 2) the development of a team to support goal attainment 3) implementing the plans 4) preparation for exiting RENEW.~Youth group The group is structured around the same agenda each time, starting with a presentation round, followed by an activity within the topic of the day, and finishing with sharing experiences of the activity in plenum. The young people can find inspiration regarding themes and exercises in the RENEW manual.
Study: NCT03769311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Monoclonal antibody against epidermal growth factor receptor (EGFR)
Study: NCT02785614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trazodone hydrochloride prolonged-release tablet
Description: 150 mg, oral administration, 1 per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trazodone hydrochloride prolonged-release tablet
Description: 150 mg, oral administration, 1 per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trazodone hydrochloride tablet
Description: 50mg, oral administration 3 times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trazodone hydrochloride tablet
Description: 50mg, oral administration 3 times per day
Study: NCT00837603

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Controlled home ergometer training
Study: NCT01799434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill run
Study: NCT01762813

Intervention type: PROCEDURE
Intervention: open and laparoscopic surgery
Description: Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
Study: NCT04538313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor infiltrating lymphocyte
Description: Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor infiltrating lymphocyte
Description: Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor infiltrating lymphocyte
Description: Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients.
Study: NCT03239015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is an FDA/CFDA approved targeted drugs used for Her2 amplification based on NGS results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxazolidine
Description: Oxazolidine is an FDA/CFDA approved targeted drugs used for ALK or ROS-1 or MET fusion based on NGS results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an FDA/CFDA approved targeted drugs used for BRCA1/2 mutation based on NGS results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is an FDA/CFDA approved targeted drugs used for mTOR or PI3KCA mutation based on NGS results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is an FDA/CFDA approved targeted drugs used for RET mutation based on NGS results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is an FDA/CFDA approved targeted drugs used for CDK4/6 mutation or amplification based on NGS results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/L1 inhibitor plus anti-angiogenic agent
Description: PD-1/L1 inhibitor plus anti-angiogenic agent is a regimen used for refractory tumor without druggable target
Study: NCT02583776

Intervention type: DEVICE
Group type: OTHER
Intervention: Blinded - CGM
Description: Data from device will be blinded and alarms off
Study: NCT05339620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant driver facilitated micro-osteoperforations
Description: 3 micro-osteoperforations(in a vertical pattern) are done on the randomly allocated experimental side , distal to canine under local anesthesia. the other side of the mouth is used as a control.~alginate impression is taken before the intervention .
Study: NCT01272869

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenSura
Description: The ostomy bag filter will be tested for a period of 14 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morfeus
Description: The new ostomy bag filter will be tested for a period of 14 days
Study: NCT03442582

Intervention type: BIOLOGICAL
Intervention: Afluria Influenza Vaccine
Description: Afluria is a seasonal influenza vaccine~Vaccine exposure in routine care (no vaccination per protocol)
Study: NCT05339620

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant driver facilitated micro-osteoperforations
Description: 3 micro-osteoperforations(in a vertical pattern) are done on the randomly allocated experimental side , distal to canine under local anesthesia. the other side of the mouth is used as a control.~alginate impression is taken before the intervention .
Study: NCT00919776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: prednisolone 40mg daily then reducing regimen over 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclosporin
Description: Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
Study: NCT01893554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV ΔNS2 Δ1313 I1314L Vaccine
Description: For participants in Groups 1, 3, and 4: 10\^6 plaque forming units (PFU) of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).~For participants in Group 2: 10\^5 PFU of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
Study: NCT00837759

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin

Intervention type: DRUG
Group type: OTHER
Intervention: Lansoprazole

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Diamyd

Intervention type: DRUG
Group type: OTHER
Intervention: GAD65 (Diamyd)
Study: NCT02189278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Intervention
Description: Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
Study: NCT02975726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis Catheter
Description: Peritoneal dialysis catheter insertion in order to drain access fluid within the belly for patients with liver cirrhosis and refractory ascites.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large Volume Paracentesis
Description: Insertion of a needle into the peritoneal cavity where ascites accumulates, then attaching the needle to a collection system that drains the ascites by gravity. This procedure is part of the standard care for the treatment of refractory ascites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25% Human Serum Albumin injection
Description: Patients will be given Human Serum Albumin after the initial drain of ascites fluid: 100cc for 5-10L drainage, 200cc for 10-15L drainage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bloodwork
Description: Monthly bloodwork will be done as part of usual standard of care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bloodwork
Description: Monthly bloodwork will be done as part of usual standard of care.
Study: NCT03622320

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin
Study: NCT01893554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV ΔNS2 Δ1313 I1314L Vaccine
Description: For participants in Groups 1, 3, and 4: 10\^6 plaque forming units (PFU) of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).~For participants in Group 2: 10\^5 PFU of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV ΔNS2 Δ1313 I1314L Vaccine
Description: For participants in Groups 1, 3, and 4: 10\^6 plaque forming units (PFU) of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).~For participants in Group 2: 10\^5 PFU of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV ΔNS2 Δ1313 I1314L Vaccine
Description: For participants in Groups 1, 3, and 4: 10\^6 plaque forming units (PFU) of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).~For participants in Group 2: 10\^5 PFU of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
Study: NCT00416572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: Sessions were led by two professionals with expertise in the topic. The sessions began a with presentation of informational material followed by guided discussion of related topics. The first session discussed what to say and not say to children about cancer and how to create a safe environment for them; the second session discussed carrying on with life after the diagnosis of breast cancer, including strategies for managing stress and anxiety and developing meaning in life; the third session talked about how to maintain closeness with a partner and ways to talk about breast cancer; the last session focused on the effects of treatment on reproductive status, and the genetic bases of breast cancer. Participants were also given related booklets and brochures to take home to read.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education Intervention
Description: The nutrition sessions were presented by a professional trained in nutritional science. Sessions included the presentation of information and guided discussion of related topics. The first session discussed information on choosing fruits, vegetables, and low-fat foods and incorporating them into a diet; the second session involved a demonstration of low-fat cooking methods; the third session provided information on the nutritional make-up of a healthy diet and how to shop for it; the last session included information on how to maintain a healthy, low-fat diet while eating out. Women were also asked to keep a four-day food diary, to focus them on their dietary intake and control over it.